Portfolio Lab

Roivant Sciences Ltd.

  • Stock
  • Ticker ROIV
  • ISIN BMG762791017
  • Nasdaq
  • US listing in dollars

Health care · Pharmaceuticals · USA

$38.66 −0.78%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Roivant Sciences Ltd. since 10/2021, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

ROIVGlobal equities (VT)

$10,000 grew to $48,684. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −79.2% in 05/2022, measured from the peak in 12/2021. It took 45 months to get back to the old peak.

1-year return
+90.7%
5-year return p.a.
+37.0%
Return p.a. since 10/2021
+31.8%
Volatility p.a.
59.0%
Largest decline
−79.2%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue9.07.62.21.62.02.51.435
Gross profit–––1.5–––32
Operating income-274-285-285-306-339415-366-268
EBITDA-271-284-284-305-338416-365-267
Net income169-206-223-114-266303-190-192
Earnings per share0.23-0.29-0.33-0.17-0.380.34-0.26-0.27
Balance sheet
Total assets5,7925,4375,0335,0635,2255,7095,3064,976
Liabilities256250217257251416385380
Equity5,1894,6884,3464,3624,2694,5274,2314,020
Cash1,9912,7151,2381,2371,4781,4191,2481,642
Cash flow
Operating cash flow-207-173-204-186-196-164-271594
Capital expenditure-1.8-0.8-4.0-7.84.9-1.3-0.4-0.2
Free cash flow-209-173-208-194-192-165-271594

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2025 at +83.4%, weakest 2022 at −20.7%. 3 of 4 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
9 Nov 2026−$0.27
6 Aug 2026−$0.26
20 May 2026$0.34
6 Feb 2026−$0.38
10 Nov 2025−$0.17
11 Aug 2025−$0.33
29 May 2025−$0.29
10 Feb 2025$0.23
12 Nov 2024−$0.31
9 Aug 2024$0.12
30 May 2024−$0.23
13 Feb 2024$6.03

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€25bn
Market cap in trading currency
$28.0bn
Enterprise value
$23.8bn
P/E
–
P/S
681.76
P/B
6.97
EV/Sales
579.34
EV/EBITDA
–
Earnings yield
–
FCF yield
-0.1%

Results (last four quarters)

Revenue
$41.1m
Gross profit
–
EBITDA
−$555m
Net income
−$344m
Earnings per share
−$0.57
Revenue per share
$0.06
Revenue growth
+2,135.6%
Earnings growth
–

Profitability

Gross margin
–
Operating margin
-1,358.1%
Net margin
-838.2%
Return on equity
-8.2%
Return on assets
-6.9%

Balance sheet and cash flow

Cash
$4.21bn
Cash per share
$5.81
Financial debt
–
Debt/equity %
–
Current ratio
15.56
Book value per share
$5.55
Operating cash flow
−$36.4m
Free cash flow
−$33.3m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
725m
Volume
3.97m
Avg. volume 3 months
8.13m
Relative volume
0.5

Price and technicals

Price
$38.66
1 day
−0.8%
52-week high
$41.85
52-week low
$20.10
Distance to 52-week high
−7.6%
Distance to 52-week low
+92.3%
Distance to 50-day line
+4.0%
Distance to 200-day line
+18.1%
RSI (14)
53
Volatility 1M
45.7%

Performance

1 week
−2.2%
1 month
+3.2%
3 months
+6.3%
6 months
+29.0%
YTD
+78.1%
1 year
+90.0%

Dates

Fiscal year end
31 Mar 2026
Most recent quarter
30 Sep 2026

Frequently asked questions

How has ROIV performed since 10/2021?

$10,000 grew to $41,342 by 20 Nov 2026, which is +31.8% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is ROIV?

Volatility was 59.0% per year, measured on monthly returns. The largest decline from a peak was −79.2%, with the low in 05/2022.

How does ROIV compare with a broad equity ETF?

Over the same period Global equities (VT) returned +8.6% per year at 15.3% volatility, ROIV returned +31.8% at 59.0%. The correlation of monthly returns was 0.35; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Why does this page show a US listing?

The figures use the stock's listing traded in the US. On individual days its path differs slightly from the price on the home exchange.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Roivant Sciences Ltd. (ROIV): Return and risk